Graviton
A bioscience corportation
About Graviton
Graviton Bioscience Corp., a clinical-stage biotechnology company headquartered in New York, was established in 2020 by the seasoned biotech entrepreneur Dr. Samuel Waksal. Dr. Waksal's extensive background includes founding ImClone Systems, which was later acquired by Eli Lilly, and Kadmon Pharmaceuticals, acquired by Sanofi. His experience at Kadmon was particularly pivotal as he led the development of the first approved ROCK2 inhibitor, a class of drugs central to Graviton's focus.
The company directs its efforts toward discovering and developing novel therapies for a range of serious conditions, including fibrotic, autoimmune, and central nervous system (CNS) diseases. Graviton's scientific approach centers on inhibiting the Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), a protein implicated in the pathology of numerous disorders that currently have inadequate or no treatment options. The business model is rooted in intensive research and development to create a pipeline of drug candidates. Revenue generation is anticipated through strategic partnerships, licensing agreements, and eventual commercialization of its therapies.
Graviton's lead drug candidate, GV101, is a selective ROCK2 inhibitor currently progressing through clinical trials. This compound has demonstrated an ability to penetrate the blood-brain barrier in preclinical studies and has shown a favorable safety profile in early clinical trials. The company's strategy involves forging collaborations with major pharmaceutical firms to accelerate development and commercialization. Notable partnerships include a strategic investment from Sanofi, which grants them the right of first negotiation to license compounds, and alliances with Ovid Therapeutics and Sino Biopharmaceutical Limited to advance ROCK2 inhibitors for specific indications like Cerebral Cavernous Malformations and other CNS diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jan 2024 | $0 | — | Sanofi | ↗ |
| EARLY VCOther financing | Dec 2023 | $35M | $199M | Enavate Sciences | ↗ |
Growth signals
Latest recorded traffic for Graviton is 710 monthly website visits, down 45.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Graviton in the New York City ecosystem
The Graviton office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Enavate Sciences
Sanofi
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Graviton on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Graviton’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









